STATE of BIO

Methodology: Each Funnel-A candidate is a drug approved by a foreign regulator whose active moiety has never been approved in the US. Bars group the candidates by how many EEA countries authorise them (from the EMA Article 57 register) — a proxy for how established a medicine is. Real output of the RareDiseaseHedge pipeline.

Methodology: Illustrative split of the disease areas that have historically earned rare-pediatric vouchers, sized to the design. Outer ring shows representative sub-areas. Shape is for demonstration — not pipeline output.

Methodology: Bubble area is proportional to how many of the never-US candidates each country authorises, from the EMA Article 57 register plus Health Canada and Swissmedic. Real pipeline output.